BVS
Bioventus Inc.
$12.22
+0.11 (+0.91%)
At close · Jul 9
Market Cap
$992.39M
Shares
83,534,785
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.22
Open$12.13
Day$11.68–12.30
52W$5.81–12.30
Avg vol 30d741K
Short int2.2M · 2.6% float · 3.3d
Short vol63%
Last earningsMay 6, 2026
DataFeb 2021–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+46%
above
Price vs 50-day avg
+26%
above
RSI (14)
75
overbought
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+33%
trailing
6-month return
+58%
trailing
YTD return
+64%
this year
Relative strength
+49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Distributing
3 of 156 funds reported for Jun 30 · net -1.6K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.61% of float · ▲ +13.2% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
−1%
Y/Y
Gross margin
68%
expanding
EPS growth
+159%
Y/Y
Free cash flow
$72.1M
Valuation
P/E 29
in line
Balance sheet
$306.4M
net debt
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Net sales
· twelve months ending December 31, 2026
Initiated
$600M – $610M
prior FY $568.09M
midpoint +6.5% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+46%
Bullish
Price vs 50-day avg
+26%
Bullish
RSI (14)
75
Bearish
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Distributing
3 of 156 funds reported for Jun 30 · net -1.6K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.61% of float · ▲ +13.2% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $12 · 99%
52-wk high $12
vs 200-day avg +46%
vs 50-day avg +26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash from operations | $8.9M | Q1 | — |
| adjusted EBITDA non-GAAP | $24M | Q1 2026 call | — |
| adjusted EBITDA margin non-GAAP | 18% | Q1 2026 call | — |
| adjusted EPS non-GAAP | $0.15 | Q1 2026 call | — |
| adjusted gross margin non-GAAP | 76% | Q1 2026 call | — |
| adjusted net income non-GAAP | $13M | Q1 2026 call | — |
| adjusted operating income non-GAAP | $20M | Q1 2026 call | — |
| cash flow from operations | $9M | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BVS
this stock
Bioventus Inc.
|
$992.39M | +64.2% | +0.0% | 29.0 | 2.6% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -6.7% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -13.5% | +8.4% | 22.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.54B | -52.8% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BVS | +24.1% | +32.8% | +57.9% | +29.5% | +64.3% |
| SPY | +0.8% | +2.0% | +8.9% | +0.7% | +10.2% |
| vs SPY | +23.3% | +30.8% | +49.0% | +28.8% | +54.0% |